Aimmune Therapeutics (AIMT): Palisade Trial Completing Enrollment Early Shows Excitement For Therapy - Wedbush

September 21, 2016 7:42 AM EDT
Get Alerts AIMT Hot Sheet
Price: $15.00 +6.08%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 9 | New: 77
Trade AIMT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Aimmune Therapeutics (NASDAQ: AIMT) after the Phase 3 PALISADE trial completed enrollment 3 months ahead of schedule.

Aimmune announced it has exceeded its target of enrolling 350 peanut allergic patients in the U.S. and Canada in the PALISADE trial and expects final enrollment to be 425-450 patients. The PALISADE trial is designed to enroll approximately 500 peanut allergic patients, aged 4-55 years, from North American and Europe. The analyst believes that the trial completing enrollment ahead of schedule speaks to the excitement surrounding AR101 and indicates that doctors and patients are not overly concerned about potential GI intolerability issues given AR101’s robust efficacy.

Aimmune also announced that it plans to initiate the RAMSES trial in Q1:17, to assess the real-world application of AR101. The analyst believes the study is likely to ease regulatory concerns while aiding in commercial adoption of AR101. RAMSES is a double blind, placebo controlled trial, slated to enroll ~400 patients from the U.S..

No change to the price target of $42.

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $15.81 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Liana Moussatos

Add Your Comment